Kheiron
acquired by DeephealthEntrepreneur First '16London, GB · Founded 2016 · 7 known investors
Kheiron Medical Technologies developed AI-powered breast cancer diagnostic tools, including Mia™, which assisted radiologists in breast screening decision-making. The company was acquired by DeepHealth in 2024 and its technology now supports SmartMammo™, an AI solution for breast cancer diagnostic workflows.
Also known as Kheiron Medical · Kheiron Medical Technologies · Kheiron Medical Technologies Limited
Founders & leadership
Kheiron was founded in 2016 by Peter Kecskemethy and Tobias Rijken.
Investors · 7
Company profile
researched Aug 2026Kheiron Medical Technologies Limited was a London, UK-headquartered artificial intelligence company that applied deep learning, data science and radiology insights to mammography, with the stated mission of helping breast cancer patients live longer through earlier detection. Its principal product was Mia™ (Mammography Intelligent Assessment), a suite of AI solutions for breast cancer screening that supported radiologists in screening decision-making and could be deployed as an independent reader, a concurrent reader, or a triage tool [0][5].
The company positioned its tools to improve the efficiency, consistency and accuracy of radiology reporting for radiologists, radiology departments and hospitals, including by acting as an independent second reader of mammography x-ray images [1][2][3]. Mia™ received CE marking in Europe in 2019 and was described as delivering double-reading quality with a single human reader; it was deployed in what DeepHealth described as the EU and UK's first prospective evaluation of a breast screening AI solution [0][5].
In 2024 Kheiron became part of DeepHealth, an AI-powered health informatics company that is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT). DeepHealth said Kheiron's technology and clinical validation would complement its existing breast cancer portfolio, including Smart Mammo™/SmartMammo™, and accelerate the introduction of its breast cancer solutions in Europe [0][5].
Founding story
Kheiron Medical Technologies was founded in 2016 in London by co-founders Tobias Rijken and Peter Kecskemethy, with a vision to use deep learning and data science to support radiologists in detecting breast cancer earlier and more accurately. According to the founders, the company name derives from Kheiron, a figure in Greek mythology that was part man and part horse, known for his knowledge and skill in medicine [0][3][5].
Business model
Kheiron developed and supplied AI software tools for radiologists, radiology departments and hospitals, intended to integrate into breast cancer screening workflows as an independent reader, concurrent reader or triage tool [0][1][3].
Traction
Mia™ obtained CE marking in Europe in 2019 and was deployed in the EU and UK's first prospective evaluation of a breast screening AI solution, which DeepHealth characterized as showing strong results. The company won the AI in Health and Care Award in 2020 [0][5].
Latest developments
DeepHealth announced the acquisition of Kheiron on 22 October 2024, and the kheironmed.com website now redirects visitors to DeepHealth and its SmartMammo™ breast screening solution. In April 2025 RadNet announced an all-stock merger agreement to acquire iCAD, Inc., completed by DeepHealth in July 2025, further expanding the group's breast health AI portfolio [0][5].
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Kheiron was one of several AI companies targeting breast cancer screening; a startup directory lists Aidoc, Lunit and Viz.ai as competitors. Following its acquisition, its technology was folded into DeepHealth's breast cancer screening portfolio alongside SmartMammo™, and DeepHealth's parent RadNet subsequently agreed to acquire another breast health AI provider, iCAD, completing that transaction in July 2025 [0][4][5].
Kheiron's Mia™ was CE-marked and validated to deliver double-reading quality with a single human reader, and was used in what DeepHealth described as the EU and UK's first prospective evaluation of a breast screening AI solution. It could be used flexibly as an independent reader, a concurrent reader, or a triage tool [0][5].
Technology
The company combined deep learning methods, data science and radiology insights, alongside machine learning and high-performance computing expertise, to detect malignancies in mammogram x-ray images. Its Mia™ product was CE-marked and was described as delivering double-reading quality with a single human reader [0][1][2][5].
Go-to-market
Kheiron worked through partnerships with healthcare and academic institutions; listed partners included Emory University, the NHS, iCAIRD, UCSF and mamma. Its technology was deployed within European and UK breast screening programs [3][5].
Radiologists, radiology departments, hospitals and population-level breast cancer screening programs [1][3][5].
Geography
Headquartered in London, United Kingdom, with offices listed at 2nd Floor, Stylus Building, 112-116 Old Street, London EC1V 9BG. Its technology was deployed in the EU and the UK, and it held membership in NEMA's Medical Imaging and Technology Alliance (MITA) [0][1][5].
History
Founded in London in 2016, Kheiron participated in the Creative Destruction Lab's CDL-Toronto Health stream in the 2018/19 cohort. Its Mia™ product received CE marking in Europe in 2019, and the company won the AI in Health and Care Award in 2020. Mia™ was subsequently deployed in what was described as the EU and UK's first prospective evaluation of a breast screening AI solution. In October 2024 Kheiron was acquired by DeepHealth, a wholly owned subsidiary of RadNet, Inc. [0][2][5].
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsDeepHealth, a wholly owned subsidiary of RadNet, Inc., announced the acquisition of Kheiron Medical Technologies Limited to expand its AI-powered cancer diagnostic and screening portfolio and accelerate the introduction of its breast cancer solutions in Europe.
Kheiron's Mia™ (Mammography Intelligent Assessment) breast screening AI product received CE marking in Europe.
Kheiron Medical Technologies was listed as a company in the CDL-Toronto Health stream for the 2018/19 cohort year.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 6
primary sources listed
- Kheironkheironmed.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Kheiron do?
- London-based developer of Mia™, a deep-learning mammography reading tool, acquired by RadNet subsidiary DeepHealth in 2024.
- Who founded Kheiron?
- Kheiron was founded by Peter Kecskemethy, Tobias Rijken in 2016.
- Who are Kheiron's investors?
- Kheiron's investors include Entrepreneur First, Greycroft, Hoxton Ventures, InHealth Ventures, Samos Investments, Village Global, Walking Ventures.
- Who acquired Kheiron?
- Kheiron was acquired by Deephealth.
- Where is Kheiron headquartered?
- Kheiron is headquartered in London, GB.